Literature DB >> 3981255

Rapid clearance of iodine-131 MIBG from the heart and liver of patients with adrenergic dysfunction and pheochromocytoma.

M Nakajo, K Shimabukuro, N Miyaji, J Shimada, K Shirono, H Sakata, H Yoshimura, R Yonekura, S Shinohara.   

Abstract

Iodine-131 MIBG, a radiolabeled adrenergic neuron-blocking agent, decreased rapidly from the heart and liver of patients with adrenergic dysfunction (n = 3) and pheochromocytoma (n = 2) when compared with eight controls. The 4-hr activity expressed as percentages (mean +/- s.d.) of the 20-min counts were as follows: 80 +/- 3.0% in the controls compared with 60 +/- 7.6% in the patients over the heart (p less than 0.01) and 79 +/- 3.2% in the controls compared with 51 +/- 17% in the patients over the liver (p less than 0.02). However, there was no significant difference in the rate of [131I]MIBG decrease in these organs between controls and patients in the intervals subsequent to 4 hr (p greater than 0.05). These findings suggest that adrenergic neuronal uptake of [131I]MIBG in these organs is smaller in the patients than in the controls. Measurements of time-activity relationships of radioiodinated MIBG may be useful for assessment of adrenergic function of these organs and thus of generalized disorders of adrenergic innervation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3981255

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  7 in total

Review 1.  Imaging of myocardial sympathetic innervation with metaiodobenzylguanidine.

Authors:  M W Dae
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

2.  Myocardial uptake of meta-[123I]-iodobenzylguanidine [( 123I]-MIBG) in patients with myocardial infarct.

Authors:  D Fagret; J E Wolf; M Comet
Journal:  Eur J Nucl Med       Date:  1989

Review 3.  Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry.

Authors:  A R Wafelman; C A Hoefnagel; R A Maes; J H Beijnen
Journal:  Eur J Nucl Med       Date:  1994-06

4.  Comparison of [123I]metaiodobenzylguanidine kinetics with heart rate variability and plasma norepinephrine level.

Authors:  C Kurata; S Shouda; T Mikami; Y Wakabayashi; T Nakano; T Sugiyama; K Tawarahara; K Sakata
Journal:  J Nucl Cardiol       Date:  1997 Nov-Dec       Impact factor: 5.952

5.  Abnormal myocardial uptake and clearance of 123I-labeled metaiodobenzylguanidine in patients with chronic renal failure and autonomic dysfunction.

Authors:  H Miyanaga; S Yoneyama; T Kamitani; S Kawasaki; T Takahashi; H Kunishige
Journal:  J Nucl Cardiol       Date:  1996 Nov-Dec       Impact factor: 5.952

6.  Measurement of myocardial accumulation of 123I-metaiodobenzylguanidine for studying cardiac autonomic neuropathy in diabetes mellitus.

Authors:  M Mäntysaari; J Kuikka; J Mustonen; K Tahvanainen; E Vanninen; E Länsimies; M Uusitupa
Journal:  Clin Auton Res       Date:  1996-06       Impact factor: 4.435

7.  The impact of acquisition time of planar cardiac (123)I-MIBG imaging on the late heart to mediastinum ratio.

Authors:  Aukelien C Dimitriu-Leen; Alessia Gimelli; Imad Al Younis; Caroline E Veltman; Hein J Verberne; Ron Wolterbeek; Silvia Zandbergen-Harlaar; Jeroen J Bax; Arthur J H A Scholte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-29       Impact factor: 9.236

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.